Published in Cancer Weekly, December 27th, 2005
The trial is designed to evaluate the safety and preliminary efficacy of PV-10 in five patients with recurrent breast carcinoma. Each patient enrolled in the study is having PV-10 injected into one or more tumors, which are observed for a period of 1-3 weeks thereafter. The patients then undergo standard surgery to remove their tumors, allowing thorough assessment of the effects of PV-10 in breast cancer tissue and surrounding normal tissue.
The trial is being...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.